SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (3297)12/12/1997 10:31:00 AM
From: Zirdu  Read Replies (2) | Respond to of 6136
 
It is interesting that "the market" may not be too interested in what drugs AGPH may have ready for 2001, but that it is very interested (and apparantly very negative) on the prospects for continued viability of Viracept in the year 2001. Contradictory, don't you think?

RR



To: David S. who wrote (3297)12/12/1997 8:50:00 PM
From: Oliver & Co  Respond to of 6136
 
If that is true, then why are the analysts taken it into consideration? If you remember one of the reasons David Crossen downgraded AGPH back in October was because he expected Viracept sales in 2001, and 2002 to decrease.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News